Everyone deserves to live a healthy life. Yet all too often disease or inequities in access to care compromise a person’s health.
We are proud that our actions and collaborations to address diseases like HIV, tuberculosis and Ebola which disproportionately impact some of world’s most underserved communities continue to be recognized as industry leading by the Access to Medicine Index (ATMI).
As the world’s largest healthcare company, enabled by a dedicated global public health team we continuously challenge ourselves to apply our expertise and partnering power to expand global equitable access to medicines in low- and middle-income countries; innovating across all that we do to develop and deliver much-needed medicines, strengthen health systems and support frontline health workers.
Alongside the depth and breadth of J&J’s resources, it is our long-standing expertise in tackling global health challenges that has laid the groundwork and is enabling our comprehensive, rapid and equitable response to the COVID-19 pandemic.
As the world faces down COVID-19 and comes to terms with the inequities left in its wake, we are committed, more than ever before, to harnessing every resource at our disposal toward advancing a safer, healthier and more equitable world where everyone can thrive.